Algert Global LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 14.5% in the

Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) durin

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform a

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy

OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond dri

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report)

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expa

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform a

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and r

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen'

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raise

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Thera

Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch

U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, follo

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and main

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutic

First approved treatment for thyroid eye disease (TED) with labeling that includes data for both act

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compa

OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or t

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

https://www.sec.gov/ix?doc=/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Co

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a prim

Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with

OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compan

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform a

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.90) per share which beat the an

- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect -- Eleg

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy

Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and l

Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen I

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lo

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform a

Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over